PureIMS receives a grant of € 41.028,58 to initiate the development of a new dry powder inhaler (DPI). This new DPI will contain an innovative dispersion mechanism to enable delivery of medicines such as antibiotics, vaccines, and biologics. Unlike current devices, it will be user-friendly and suitable for vulnerable groups like children and elderly patients.
The inhaler uses aerodynamic shear and friction forces to break up powders into fine aerosols that can reach deep into the lungs. A prototype will be designed, manufactured, and tested in vitro with advanced laboratory techniques such as laser diffraction and cascade impaction.
Key challenges include technical limits of prototype manufacturing, ensuring efficient powder dispersion, and reliable aerosol characterization. These will be tackled through iterative design and close collaboration with experienced partners.
The result will be a validated prototype that demonstrates the working principle in the lab. While not yet ready for commercial use, it forms the foundation for large-scale production and clinical proof-of-concept studies, opening the way to broader therapeutic options for many patients.
